MENLO PARK, Calif., April 23, 2024 /PRNewswire/ -- Cyngn Inc. ("Cyngn", NASDAQ: CYN) has been chosen to supply its DriveMod Tuggers for industrial automation to John Deere's operation in Dubuque, Iowa. Cyngn is a supplier of AI-powered autonomous vehicle and data solutions based in Menlo Park, CA.

Company has improved its balance sheet by $27 million over the past 90 days Chairman and CEO has converted all $17.22 million of his debt into equity Company bolsters balance sheet with $5.25 million capital infusion CHESAPEAKE, Va., April 23, 2024 /PRNewswire/ -- Greenwave Technology Solutions, Inc. ("Greenwave" or the "Company") (Nasdaq: GWAV), a leading operator of metal recycling facilities in Virginia, North Carolina, and Ohio, announced today that on April 22, 2024, it further strengthened its balance sheet by approximately $12 million.

SINGAPORE, April 23, 2024 /PRNewswire/ -- Tungray Technologies Inc (the "Company" or "Tungray") (NasdaqCM: TRSG), a provider of customized industrial manufacturing solutions to Original Equipment Manufacturers (OEMs) in the semiconductors, printers, electronics, and home appliances industries, today announced the closing of its initial public offering (the "Offering") of 1,250,000 Class A ordinary shares at a public offering price of $4 per share. The Class A ordinary shares began trading on Nasdaq Capital Market under the ticker symbol "TRSG" on April 19, 2024.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that recently reported twelve-month follow-up data from its Phase 2a trial of Descartes-08 in patients with generalized myasthenia gravis will be featured during an oral presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024 in Baltimore, MD. Descartes-08, the Company’s lead product candidate, is an autologous anti-B cell maturation antigen (BCMA) mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T).